Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas.

Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas. Br J Dermatol. 2019 May 06;: Authors: Ellis R, Tang D, Nasr B, Greenwood A, McConnell A, Anagnostou ME, Elias M, Verykiou S, Bajwa D, Ewen T, Reynolds NJ, Barrett P, Carling E, Watson G, Armstrong J, Allen AJ, Horswell S, Labus M, Lovat PE Abstract BACKGROUND: Despite the recent update to the AJCC staging criteria for melanoma, this system is still unable to identify truly high-risk stage I tumour subsets. OBJECTIVE: To determine clinical utility of combined epidermal AMBRA1/Loricrin (AMLo) expression as a prognostic biomarker for AJCC stage I cutaneous melanoma. METHODS: Peri-tumoural AMBRA1 expression was evaluated in a retrospective discovery cohort of 76 AJCC I melanomas. Multivariate analysis of AMLo expression was subsequently correlated with clinical outcomes up to 12-years in two independent powered, retrospective validation and qualification cohorts comprising of 379 AJCC I melanomas. RESULTS: Decreased AMBRA1 expression in the epidermis overlying primary melanomas in a discovery cohort of 76 AJCC I tumours was associated with 81.5% 7-year DFS versus 100% survival with maintained AMBRA1; P
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research

Related Links:

ConclusionsDGBX significantly alleviates abnormal tumor-induced EPC accumulation, inhibits B16 melanoma progression, and enhances anti-tumor immune responses.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: August 2019Source: Biomedical Signal Processing and Control, Volume 53Author(s): Saptarshi Chatterjee, Debangshu Dey, Sugata Munshi, Surajit GoraiAbstractThis paper proposes a systematic approach for the feature extraction and subsequent classification of benign and malignant skin diseases of both the melanocytic and epidermal lesion categories from dermoscopic images. For this purpose, melanoma and nevus are considered as representatives of the melanocytic skin lesion category, whereas basal cell carcinoma (BCC) and seborrheic keratoses (SKs) are included under the epidermal lesion category. The present ...
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
Abstract Recent reports describe how genome-wide transcriptional analysis of cancer tissues can be exploited to identify molecular signatures of immune infiltration in cancer. We hypothesize that immune infiltration in cancer may also be defined by changes in certain epigenetic signatures. In this context, a primary objective is to identify site-specific CpG markers whose levels of methylation may be highly indicative of known transcriptional markers of immune infiltration such as GZMA, PRF1, T cell receptor genes, PDCD1, and CTLA4. This has been accomplished by integrating genome-wide transcriptional expression a...
Source: Advances in Cancer Research - Category: Cancer & Oncology Authors: Tags: Adv Cancer Res Source Type: research
Conditions:   Melanoma;   Hodgkin Lymphoma;   Non Small Cell Lung Cancer Intervention:   Sponsor:   University of Cologne Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Stage III and IV Melanoma Intervention:   Biological: Dengue-1 #45AZ5 Sponsors:   PrimeVax Immuno-Oncology Inc.;   Advocate Lutheran General Hospital;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Oregon State University) Researchers have found a possible counterpunch to the drug resistance of melanoma, the most dangerous form of skin cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractExtramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required.In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane‐ and/or platinum‐based regimen...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Melanoma and Cutaneous Malignancies Brief Communications Source Type: research
We present an illustrative case of a 60‐year‐old man with metastatic melanoma who presented with AKI during treatment with nivolumab and review the literature to address frequently asked questions concerning the diagnosis and management of renal irAEs in patients with advanced cancer. Importantly, most patients will recover completely, and some may tolerate a rechallenge of ICI therapy, with prompt and effective treatment.Key Points. Renal immune‐related adverse events (irAEs) are less frequently reported than other irAEs; however, it is possible that available data underestimate their true incidence because of misse...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: New Drug Development and Clinical Pharmacology Immune ‐ Related Adverse Events Source Type: research
Amyloidosis cutis dyschromica (ACD) is a clinicopathologic form of primary localized cutaneous amyloidosis (PLCA) which is considered to be autosomal recessive and characterized by prepubertal onset of reticular hyperpigmentation with hypopigmented spots, along with amyloid deposition in the papillary dermis. Recently, bi-allelic mutations in GPNMB, encoding glycoprotein (transmembrane) non-metastatic melanoma protein b have been described in ACD (Yang et al., 2018). In contrast, we describe three pedigrees with ACD in whom we identified semi-dominant GPNMB mutations thereby expanding the inheritance pattern of this disorder.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research
Gangemi Among Uveal Melanoma (UM) driver mutations, those involving GNAQ or GNA11 genes are the most frequent, while a minor fraction of tumors bears mutations in the PLCB4 or CYSLTR2 genes. Direct inhibition of constitutively active oncoproteins deriving from these mutations is still in its infancy in UM, whereas BRAFV600E-targeted therapy has obtained relevant results in cutaneous melanoma. However, UM driver mutations converge on common downstream signaling pathways such as PKC/MAPK, PI3K/AKT, and YAP/TAZ, which are presently considered as actionable targets. In addition, BAP1 loss, which characterizes UM metastati...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Dermatology | Melanoma | Skin | Skin Cancer | UK Health